立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

003020 立方制药

已收盘 11-29 15:00:00

{"stockData":{"symbol":"003020","market":"SZ","secType":"STK","nameCN":"立方制药","latestPrice":19.4,"timestamp":1732863798000,"preClose":19.24,"halted":0,"volume":2016837,"delay":0,"floatShares":138000000,"shares":192000000,"eps":0.9098,"marketStatus":"已收盘","marketStatusCode":5,"change":0.16,"latestTime":"11-29 15:00:00","open":19.26,"high":19.59,"low":19.12,"amount":39164900,"amplitude":0.0244,"askPrice":19.41,"askSize":110,"bidPrice":19.4,"bidSize":356,"shortable":0,"etf":0,"ttmEps":0.9098,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1733103000000},"adr":0,"adjPreClose":19.24,"symbolType":"stock","openAndCloseTimeList":[[1732843800000,1732851000000],[1732856400000,1732863600000]],"highLimit":21.16,"lowLimit":17.32,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":191571763,"pbRate":2.13,"roa":"--","roe":"6.96%","epsLYR":1.42,"committee":0.338462,"marketValue":3716000000,"floatMarketCap":2680000000,"peRate":21.323368,"changeRate":0.0083,"turnoverRate":0.0146,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-12-02。"},"requestUrl":"/m/hq/s/003020","defaultTab":"news","newsList":[{"id":"2486022355","title":"立方制药(003020.SZ)：美阿沙坦钾原料药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486022355","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486022355?lang=zh_cn&edition=full","pubTime":"2024-11-26 18:10","pubTimestamp":1732615838,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药(003020.SZ)公告，公司收到国家药品监督管理局下发的美阿沙坦钾原料药上市申请《受理通知书》。公告显示，美阿沙坦钾是一种前体药物，口服吸收后可迅速转化为活性成分阿齐沙坦，其制剂用于治疗成人原发性高血压，由武田药品工业株式会社研制开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2486759022","title":"立方制药最新公告：美阿沙坦钾原料药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486759022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486759022?lang=zh_cn&edition=full","pubTime":"2024-11-26 18:09","pubTimestamp":1732615790,"startTime":"0","endTime":"0","summary":"立方制药公告，公司收到国家药品监督管理局下发的美阿沙坦钾原料药上市申请《受理通知书》。美阿沙坦钾是一种前体药物，口服吸收后可迅速转化为活性成分阿齐沙坦，其制剂用于治疗成人原发性高血压。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112600031886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2484327993","title":"立方制药（003020）11月19日主力资金净买入187.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484327993","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484327993?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:24","pubTimestamp":1732001040,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月19日收盘，立方制药报收于19.99元，上涨6.16%，换手率2.38%，成交量3.29万手，成交额6420.26万元。11月19日的资金流向数据方面，主力资金净流入187.84万元，占总成交额2.93%，游资资金净流入206.5万元，占总成交额3.22%，散户资金净流出394.33万元，占总成交额6.14%。立方制药主营业务：药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900019215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2482194242","title":"立方制药（003020）105.64万股限售股将于11月11日解禁，占总股本0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482194242","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482194242?lang=zh_cn&edition=full","pubTime":"2024-11-11 08:02","pubTimestamp":1731283378,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，立方制药于11月11日将有105.64万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.55%。最近一年内，该股累计解禁4202.55万股，占总股本的21.94%。本次解禁后，公司还有5340.69万股限售股份，占总股本27.88%。立方制药主营业务：药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100001082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2480265379","title":"立方制药11月4日现1笔大宗交易 成交金额287万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480265379","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480265379?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:00","pubTimestamp":1730710800,"startTime":"0","endTime":"0","summary":"　　11月4日，立方制药收涨0.98%，收盘价为18.51元，发生1笔大宗交易，合计成交量17.39万股，成交金额287万元。　　第1笔成交价格为16.50元，成交17.39万股，成交金额287.00万元，溢价率为-10.86%，买方营业部为申万宏源证券有限公司合肥潜山路证券营业部，卖方营业部为申万宏源证券有限公司安徽分公司。　　进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为1123.75万元。该股近5个交易日累计下跌4.14%，主力资金合计净流入1566.2元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-04/doc-incuwwwc2122354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2480071127","title":"11月1日立方制药现415.25万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2480071127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480071127?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:01","pubTimestamp":1730451712,"startTime":"0","endTime":"0","summary":"证券之星消息，11月1日立方制药发生大宗交易，交易数据如下：大宗交易成交价格16.61元，相对当日收盘价折价9.38%，成交25万股，成交金额415.25万元，买方营业部为申万宏源证券有限公司合肥潜山路证券营业部，卖方营业部为民生证券股份有限公司安徽分公司。截至2024年11月1日收盘，立方制药报收于18.33元，下跌0.65%，换手率1.71%，成交量2.35万手，成交额4308.46万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100031113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2479797287","title":"立方制药10月31日现1笔大宗交易 成交金额421.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479797287","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479797287?lang=zh_cn&edition=full","pubTime":"2024-10-31 16:40","pubTimestamp":1730364000,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　第1笔成交价格为16.86元，成交25.00万股，成交金额421.50万元，溢价率为-8.62%，买方营业部为申万宏源证券有限公司合肥潜山路证券营业部，卖方营业部为民生证券股份有限公司安徽分公司。　　进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为421.5万元。该股近5个交易日累计下跌1.65%，主力资金合计净流出124.93万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-31/doc-incumwna4037716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2479403520","title":"立方制药(003020.SZ)发布前三季度业绩，净利润1.19亿元，同比下降30.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479403520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479403520?lang=zh_cn&edition=full","pubTime":"2024-10-29 19:33","pubTimestamp":1730201591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药(003020.SZ)发布2024年三季度报告，前三季度，公司实现营业收入11.25亿元，同比下降26.20%。归属于上市公司股东的净利润1.19亿元，同比下降30.57%。归属于上市公司股东的扣除非经常性损益的净利润1.12亿元，同比下降24.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["003020"],"gpt_icon":0},{"id":"2479735124","title":"立方制药最新公告：前三季度净利润1.19亿元 同比下降30.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479735124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479735124?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:33","pubTimestamp":1730194393,"startTime":"0","endTime":"0","summary":"立方制药发布2024年第三季度报告，前三季度实现营业收入11.25亿元，同比下降26.20%；归属于上市公司股东的净利润1.19亿元，同比下降30.57%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900032284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020"],"gpt_icon":0},{"id":"2477010202","title":"华源证券：给予立方制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477010202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477010202?lang=zh_cn&edition=full","pubTime":"2024-10-21 07:15","pubTimestamp":1729466118,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯近期对立方制药进行研究并发布了研究报告《渗透泵控释技术领先者，精麻药、中成药驱动成长》，本报告对立方制药给出买入评级，当前股价为18.39元。我们选取心血管药物慢病龙头信立泰、精麻药物龙头恩华药业、聚焦麻醉镇痛业务的苑东生物作为可比公司，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为20.8。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102100000682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","003020"],"gpt_icon":0},{"id":"2476013014","title":"立方制药最新公告：盐酸伊伐布雷定原料药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2476013014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476013014?lang=zh_cn&edition=full","pubTime":"2024-10-18 17:19","pubTimestamp":1729243182,"startTime":"0","endTime":"0","summary":"立方制药公告，公司收到国家药监局下发的盐酸伊伐布雷定原料药上市申请《受理通知书》。盐酸伊伐布雷定是一种单纯降低心率的药物，其制剂适用于窦性心律且心率≥75次/分钟、伴有心脏收缩功能障碍的NYHAⅡ～Ⅳ级慢性心力衰竭患者等。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800030002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2476405451","title":"立方制药(003020.SZ)：盐酸伊伐布雷定原料药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2476405451","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476405451?lang=zh_cn&edition=full","pubTime":"2024-10-18 17:09","pubTimestamp":1729242559,"startTime":"0","endTime":"0","summary":"智通财金APP讯，立方制药(003020.SZ)发布公告，近日，公司收到国家药品监督管理局下发的盐酸伊伐布雷定原料药上市申请《受理通知书》。盐酸伊伐布雷定原料药上市申请获得受理，表示该品种进入注册审评阶段，对公司近期业绩不会产生重大影响。如盐酸伊伐布雷定顺利通过注册审评，将进一步丰富公司原料药产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2474606456","title":"立方制药最新公告：盐酸羟考酮缓释片取得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2474606456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474606456?lang=zh_cn&edition=full","pubTime":"2024-10-11 18:50","pubTimestamp":1728643849,"startTime":"0","endTime":"0","summary":"立方制药公告，公司收到国家药品监督管理局下发的盐酸羟考酮缓释片《药品补充申请批准通知书》，盐酸羟考酮缓释片临床上主要用于缓解持续的中度到重度疼痛。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101100031359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2469165267","title":"立方制药（003020）9月23日主力资金净卖出54.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469165267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469165267?lang=zh_cn&edition=full","pubTime":"2024-09-23 15:24","pubTimestamp":1727076290,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月23日收盘，立方制药报收于16.75元，下跌1.76%，换手率0.5%，成交量6883.0手，成交额1160.07万元。9月23日的资金流向数据方面，主力资金净流出54.36万元，占总成交额4.69%，游资资金净流入55.1万元，占总成交额4.75%，散户资金净流出0.74万元，占总成交额0.06%。立方制药主营业务：药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092300012407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2467927960","title":"首创证券给予立方制药增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2467927960","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467927960?lang=zh_cn&edition=full","pubTime":"2024-09-14 20:48","pubTimestamp":1726318080,"startTime":"0","endTime":"0","summary":"首创证券09月14日发布研报称，给予立方制药（003020.SZ，最新价：16.73元）增持评级。评级理由主要包括：1）非洛地平集采影响短期业绩表现，产品线不断丰富；2）医药工业收入恢复增长，潜力大品种有望持续放量。风险提示：潜力品种销售收入低于预期；存量产品被纳入集采，价格降幅超预期；研发进度低于预期。AI点评：立方制药近一个月获得2份券商研报关注，买入1家，增持1家，平均目标价为20.8元，与最新价16.73元相比，高4.07元，目标均价涨幅24.33%。（文章来源：每日经济新闻）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-09-14/doc-incpcuqk5014858.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-09-14/doc-incpcuqk5014858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["601136","003020"],"gpt_icon":0},{"id":"2466397882","title":"立方制药新注册《数据交换平台1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2466397882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466397882?lang=zh_cn&edition=full","pubTime":"2024-09-09 01:08","pubTimestamp":1725815285,"startTime":"0","endTime":"0","summary":"证券之星消息，近日立方制药（003020）新注册了《数据交换平台1.0》项目的软件著作权。今年以来立方制药新注册软件著作权1个。结合公司2024年中报财务数据，今年上半年公司在研发方面投入了3673.4万元，同比减14.17%。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090900000213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2464828112","title":"立方制药（003020）9月3日主力资金净卖出239.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464828112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464828112?lang=zh_cn&edition=full","pubTime":"2024-09-03 15:22","pubTimestamp":1725348150,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月3日收盘，立方制药报收于18.61元，下跌1.12%，换手率1.28%，成交量1.76万手，成交额3307.84万元。9月3日的资金流向数据方面，主力资金净流出239.29万元，占总成交额7.23%，游资资金净流入170.01万元，占总成交额5.14%，散户资金净流入69.28万元，占总成交额2.09%。立方制药主营业务：药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090300019091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2464180001","title":"立方制药（003020）9月2日主力资金净卖出524.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464180001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464180001?lang=zh_cn&edition=full","pubTime":"2024-09-02 15:17","pubTimestamp":1725261465,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月2日收盘，立方制药报收于18.82元，上涨5.49%，换手率2.7%，成交量3.69万手，成交额6946.54万元。9月2日的资金流向数据方面，主力资金净流出524.15万元，占总成交额7.55%，游资资金净流入189.03万元，占总成交额2.72%，散户资金净流入335.12万元，占总成交额4.82%。立方制药主营业务：药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090200013089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2464399810","title":"立方制药（003020）2024年中报简析：净利润减40.95%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2464399810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464399810?lang=zh_cn&edition=full","pubTime":"2024-09-01 06:20","pubTimestamp":1725142856,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期立方制药发布2024年中报。截至本报告期末，公司营业总收入7.69亿元，同比下降39.32%，归母净利润7743.09万元，同比下降40.95%。本报告期立方制药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达89.64%。去年的净利率为12.3%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090100001186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020"],"gpt_icon":0},{"id":"2463335783","title":"立方制药(003020)6月30日股东户数0.92万户，较上期减少16.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463335783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463335783?lang=zh_cn&edition=full","pubTime":"2024-08-30 17:15","pubTimestamp":1725009356,"startTime":"0","endTime":"0","summary":"证券之星消息，近日立方制药披露，截至2024年6月30日公司股东户数为9215.0户，较3月31日减少1870.0户，减幅为16.87%。在化学制药行业个股中，立方制药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.21万户。从股价来看，2024年3月31日至2024年6月30日，立方制药区间涨幅为5.04%，在此期间股东户数减少1870.0户，减幅为16.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000032276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-12-15","address":"安徽省合肥市蜀山区长江西路669号立方厂区","stockEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0358},{"period":"3month","weight":0.0874},{"period":"6month","weight":-0.0753},{"period":"1year","weight":-0.2077},{"period":"ytd","weight":-0.1573}],"companyName":"合肥立方制药股份有限公司","boardCode":"AI0051","perCapita":"676股","boardName":"批发业","registeredCapital":"19157万元","compareEarnings":[{"period":"1week","weight":0.0181},{"period":"1month","weight":0.0184},{"period":"3month","weight":0.1704},{"period":"6month","weight":0.0776},{"period":"1year","weight":0.098},{"period":"ytd","weight":0.1182}],"survey":"　　合肥立方制药股份有限公司的主营业务是药品制剂及原料药的研发、生产、销售、药品与医疗器械的批发、零售，其主要产品有非洛地平缓释片（Ⅱ）、非洛地平缓释片、甲磺酸多沙唑嗪缓释片、硝苯地平控释片、盐酸曲美他嗪缓释片、盐酸羟考酮缓释片、盐酸文拉法辛缓释片、益气和胃胶囊、亮菌口服溶液、丹皮酚软膏、克痤隐酮凝胶、金珍滴眼液。","serverTime":1732970358657,"listedPrice":23.13,"stockholders":"204204人(较上一季度增加2019.62%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供立方制药(003020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"立方制药,003020,立方制药股票,立方制药股票老虎,立方制药股票老虎国际,立方制药行情,立方制药股票行情,立方制药股价,立方制药股市,立方制药股票价格,立方制药股票交易,立方制药股票购买,立方制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供立方制药(003020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}